IP Library › Granted Patent US 12,559,532
Granted Patent B2
US 12,559,532 · App. 18/749,044 · Granted Feb 24, 2026

Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon

Inventors: Arjan Willem Griffioen (Amsterdam, NL); Elisabeth Johanna Maria Huijbers (Amsterdam, NL); Patrycja Nowak-Sliwinska (Amsterdam, NL)
Assignee: STICHTING AMSTERDAM UMC
C07K14/4748A61K39/0011A61P35/00C07K14/245C07K14/78C07K16/18C12N15/62C12Q1/6886A61K2039/55566A61K2039/585A61K2039/6068C07K2319/21C07K2319/35C12Q2600/106C12Q2600/112
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,532
App. No.
18/749,044
Granted
Feb 24, 2026
Kind
B2
Abstract

The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.

Claims (3)

1 . A method for eliciting an immune response in a mammalian subject in need of anti-tumor treatment, wherein said immune response is against a mammalian polypeptide the expression of which is associated with tumor angiogenesis, the method comprising:

administering to the subject a therapeutically effective dose of a fusion polypeptide, the fusion polypeptide comprising said mammalian polypeptide and a foreign antigen,

wherein said foreign antigen comprises the amino acid sequence of SEQ ID NO:3.

Priority Claims (1)
EP 16182827 · Aug 4, 2016 · regional
Continuity (3)
Division 18186724 · Mar 20, 2023
Continuation 16322786
Related Publication 20240409595A1 · Dec 12, 2024
References Cited (29)
US 5091513A · Huston · 1992 [cited by examiner]
US 11795202B2 · Griffioen · 2023 [cited by examiner]
US 12049484B2 · Griffioen · 2024 [cited by examiner]
US 20020115827A1 · Kim et al. · 2002 [cited by applicant]
US 20110293621A1 · Mueller et al. · 2011 [cited by applicant]
CN 1189539 · 1998 [cited by applicant]
WO 2011151721 · 2011 [cited by applicant]
Dimitrov, Ivan et a, “Bacterial immunogenicity prediction by machine learning methods.” Vaccines (2020) 8(709). [cited by examiner]
Lowe, Derek, “Not alphafold's fault.” blog “In the pipeline” entry of Sep. 7, 2022. [cited by examiner]
Guo, Haiwei H. et al, “Protein tolerance to random amino acid change.” PNAS (2004) 101(25) p. 9205-9210. [cited by examiner]
Uniprot entry A0A8J4GM89, downloaded Apr. 9, 2025. [cited by examiner]
Machine translation of CN-1189539A. [cited by applicant]
Bergmann-Leitner, et al.; “Adjuvants in the driver's seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators.” Vaccines (2014) 2 p. 252-296. [cited by applicant]
Singh, et al.; “Minimum peptide sequences necessary for priming and triggering of humoral and cell mediated immune responses in mice: use of synthetic peptide antigens of defined structure.” J. Immunol. (1980) 124(3) p.… [cited by applicant]
Yampolsky, et al.; “The exchangeability of amino acids in proteins.” Genetics (2005) 170 p. 1459-1472. [cited by applicant]
International Search Report and Written Opinion regarding International App. No. PCT/NL2017/050526, mailed Nov. 24, 2017. [cited by applicant]
International Preliminary Report on Patentability regarding International App. No. PCT/NL2017/050526, mailed Feb. 5, 2019. [cited by applicant]
European Search Report and Written Opinion regarding European App. No. 16182827, dated Jan. 12, 2017. [cited by applicant]
European Office Action regarding European App. No. 17754837.7, dated Dec. 10, 2019. [cited by applicant]
European Office Action regarding European App. No. 17754837.7, dated Jun. 12, 2020. [cited by applicant]
European Office Action regarding European App. No. 17754837.7, dated Nov. 2, 2020. [cited by applicant]
European Office Action regarding European App. No. 17754837.7, dated Jul. 26, 2021. [cited by applicant]
Henderson; “Reserchers identify new targets to control angiogenesis.” News Medical and Life Sciences (2021). [cited by applicant]
Nicosia, et al.; “Fibronectin promotes the elongation of microvesssels during angiogenesis in vivo.” J. Cell. Physiol. (1993 ) 154 p. 654-661. [cited by applicant]
Brentville, et al.; “Cirtullinated vimentin presented on MHC-II in tumor cells is a target for cd4+ t cell mediated antitumor immunity.” Cancer Res. (2016) 76(3) p. 548-561. [cited by applicant]
Huijbers, et al., “Vaccination against the extra domain-B of fibronectin as a novel tumor therapy”, The FASEB Journal, vol. 24, Nov. 2010, pp. 4535-4544. [cited by applicant]
Griffioen; “Genomic screening of the Embryo for Novel targets in the tumor Endothelium”, Marie Curie Intra-European Fellowships (IEF), Final Project Report under Grant Agreement No. 328695, May 1, 2013 to Apr. 30, 2015,… [cited by applicant]
Saupe, et al., “Vaccines targeting self-antigens; mechanisms and efficacy-determining parameters”, The FASEB Journal, vol. 29, No. 8, Jan. 2017, pp. 3253-3262. [cited by applicant]
Nap et al., “Antiangiogenesis therapy for endometriosis”, J. Cli. Endocrinol. Metab. 89, pp. 1089-1095, 2004. [cited by applicant]